Our Litigators of the Week are Sidley Austin’s Vernon Winters and David Pritikin, who came out on top in a patent fight worth billions to their client, Amgen and its subsidiary Immunex. 

Amgen makes Enbrel, a wildly successful biologic drug which has domestic sales of nearly $5 billion per year. But three Sandoz subsidiaries of global biopharma company Novartis were poised to introduce a biosimilar version of the drug—if they could prove Enbrel’s patents were invalid.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]